Frequently Asked Questions
North America dominates the anti-MAG peripheral neuropathy treatment market in the forecast period because of the rise in the government initiatives to provide better healthcare outcomes and increase in the prevalence of the disease in the market in this region.
The growth rate of the anti-MAG peripheral neuropathy treatment market is 5.0%.
Increase in diagnostic tests & increasing prevalence of ischemic heart disease are the growth drivers of the anti-MAG peripheral neuropathy treatment market.
Diagnosis, treatment, distribution channel and end-user are the factors on which the anti-MAG peripheral neuropathy treatment market research is based.
Major companies in the anti-MAG peripheral neuropathy treatment market are Alexion Pharmaceuticals, Inc. (U.S.), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), Vertex Pharmaceuticals Incorporated (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.), Amgen Inc. (U.S.), Jazz Pharmaceuticals, Inc. (U.K.), Pfizer Inc (U.S.), PerkinElmer Inc (U.S.), Bio-Rad Laboratories, Inc. (U.S.).
